Results 231 to 240 of about 281,302 (344)

Relationship between circulating levels of pancreatic proteolytic enzymes and pancreatic hormones. [PDF]

open access: yesPancreatology, 2017
Bharmal SH   +5 more
europepmc   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

open access: yesAdvanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li   +7 more
wiley   +1 more source

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao   +10 more
wiley   +1 more source

Bioorthogonal Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation

open access: yesAdvanced Science, EarlyView.
Bioorthogonal SDPTAC harnesses US‐responsive Ce6‐TCO and Tz ligands via IEDDA click chemistry to assemble degraders in situ, generating ROS that selectively eliminate nuclear, cytosolic, and membrane proteins, thereby suppressing deep‐seated tumors in vivo.
Yuhan Bao   +8 more
wiley   +1 more source

Disturbances of selected plasma proteins in Hyperdynamic Septic Shock [PDF]

open access: yes, 1982
A Ledgerwood   +38 more
core   +1 more source

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy